Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,178 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Autoimmune Disorders Clear all
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 22, 2026, 4:12 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

NCT04562766
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Rilzabrutinib, Placebo
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
10 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 4:12 PM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

NCT03895996
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AVT001, Placebo
Drug · Other
Lead sponsor
Avotres Inc.
Industry
Eligibility
16 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Jul 22, 2026, 4:12 PM EDT
Completed No phase listed Observational

BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study

NCT02662842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
FlowSmart Infusion Set, Current Infusion Set
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Escondido, California • Atlanta, Georgia • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Jul 22, 2026, 4:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251
View directory record Official record
Conditions
Cancer
Interventions
KRAS-variant and microRNA binding site mutation testing
Genetic
Lead sponsor
MiraKind
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Jul 22, 2026, 4:12 PM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 22, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional

Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature

NCT07386340
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 4:12 PM EDT
Recruiting Phase 2 Interventional

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Interventions
Efgartigimod IV, Empasiprubart IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Carlsbad, California • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients

NCT01897688
View directory record Official record
Conditions
Type 1 Diabetes, Severe Hypoglycemic Unawareness
Interventions
Islet Cell Transplant
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 4:12 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

NCT01264770
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MGA031, Sirolimus and Tacrolimus in Islet Transplantation

NCT00265473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 22, 2026, 4:12 PM EDT
Withdrawn Phase 3 Interventional

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

NCT04254380
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Gan & Lee Insulin Lispro Injection, Humalog
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
58
States / cities
Anaheim, California • Fresno, California • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation

NCT00621894
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
LGD-4665, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Manchester, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 1 Interventional

Open-label Study of Liothyronine in MS

NCT02506751
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
liothyronine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 58 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resilience-Based Program for Support Partners of Persons With Multiple Sclerosis

NCT03555253
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Resilience-Based Program for Support Partners of PwMS
Behavioral
Lead sponsor
Healios Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Flemington, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 22, 2026, 4:12 PM EDT
Not listed Phase 4 Interventional

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

NCT02270970
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
belimumab
Biological
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
16 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

NCT01358383
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
naproxen, esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.

NCT05516537
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Guidelines for Exercise in Multiple Sclerosis (GEMS), FLEX Stretching and Toning Program
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker

NCT01582139
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Heart rate informed SSM+HMM
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2014 · Synced Jul 22, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

Effect of Gain on Closed-Loop Insulin

NCT02065895
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
HIGH error, NO error, LOW error
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 22, 2026, 4:12 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

NCT06153095
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
IMPT-514
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional

Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART

NCT06405373
View directory record Official record
Conditions
Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions
ReCharge, TakeCharge
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 22, 2026, 4:12 PM EDT